Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
THX PharmaXPAR:ALTHX -1.50%31 EV-to-FCF is -48.21 as of Jul. 29, 2026. GuruFocus rates XPAR:ALTHX with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 344 Biotechnology companies, THX Pharma ranks worse than 290697.38% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, THX Pharma's Enterprise Value is €52.02 Mil.
THX Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.08 Mil. Therefore, THX Pharma's EV-to-FCF for today is -48.21.
The historical rank and industry rank for THX Pharma's EV-to-FCF or its related term are showing as below:
XPAR:ALTHX'
s EV-to-FCF Range Over the Past 10 Years
Min: -45.8 Med: 0 Max: 0
Current: -45.8
XPAR:ALTHX's EV-to-FCF is ranked worse than 100% of 344
companies
in the Biotechnology industry
Industry Median: 14.835
vs XPAR:ALTHX: -45.80
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
THX Pharma's share price for today is €3.94.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. THX Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.252.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
THX Pharma EV-to-FCF Related Terms
THX Pharma EV-to-FCF Historical Data
* Premium members only.
The historical data trend for THX Pharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ALTHX vs VRTX, REGN, RVMD: EV-to-FCF Comparison
For the Biotechnology subindustry, THX Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
THX Pharma EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, THX Pharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where THX Pharma's EV-to-FCF falls into.
THX Pharma's current Enterprise Value is €52.02 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. THX Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
THX Pharma (XPAR:ALTHX) has a EV-to-FCF of -48.21 as of Jul. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on THX Pharma and its competitors. According to the industry distribution chart, THX Pharma ranks #999999 out of 344 companies in the Biotechnology industry.
Is THX Pharma's EV-to-FCF too high?
THX Pharma's current EV-to-FCF is -48.21. Based on the distribution chart, THX Pharma ranks #999999 out of 344 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, THX Pharma has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does THX Pharma's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, THX Pharma ranks #999999 out of 344 companies for EV-to-FCF. This places THX Pharma in the lower half of its industry. The industry median EV-to-FCF is 14.84. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.84, based on 344 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on THX Pharma and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. THX Pharma's current EV-to-FCF is -48.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is THX Pharma stock overvalued right now?
THX Pharma (XPAR:ALTHX) has a current EV-to-FCF of -48.21. The current EV-to-FCF is -48.21. THX Pharma's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For THX Pharma (XPAR:ALTHX), the current EV-to-FCF is -48.21 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
THX Pharma Formerly Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company's therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson's disease, THN201 for the treatment of neurocognitive disorders in Alzheimer's disease and THN101 for neuropathic pain.
31GF Score
Get the complete analysis for XPAR:ALTHX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALTHX has been successfully added to your 
